The panel reviewed evidence from multiple single-dose HPV vaccine studies, including India IARC, Costa Rica, Doris, and Kenshe trials. Observational and randomized data consistently show robust, durable immune responses and high efficacy of single-dose schedules, particularly against HPV 16/18. Immune responses remain stable over a decade, comparable to two- or three-dose regimens. Ongoing studies (Escudo, […]
Format: Q&A Session
Stakeholder Engagement And Sustainable Delivery Platforms For Hpv Vaccination Programs – Q&A Session
The Q&A highlighted operational challenges in HPV vaccine delivery, including discrepancies in coverage data (targets vs. actuals) and high dropout rates between doses. Tanzania explained over-100% coverage as linked to outdated population estimates and mobility of school-aged girls. Experts emphasized microplanning, community health worker involvement, and electronic registries to track defaulters. Tamil Nadu shared integration […]
HPV Vaccination Programmes – Lessons Learned and Planning – Q&A Session
This Q&A followed the session “HPV Vaccination Programs: Peer Exchange on Lessons Learned from Planning and Introduction.” Participants raised practical questions to speakers from Sikkim, Sri Lanka, and Pakistan on key aspects of HPV vaccine rollout: consent models, management of out-of-school adolescents, and integration with existing health or school platforms. Discussions addressed global supply challenges, […]
The importance of effective communication and the need for a crisis communication plan – Q&A Session
The Q&A session examined lessons from past HPV vaccination challenges, focusing on misinformation crises in Ireland, Japan, and Mongolia. Participants stressed the need for rapid, decisive risk communication and stronger medical community support to prevent program collapses. Discussions highlighted cultural sensitivities around sexuality and parental perceptions influencing adolescent vaccination. Insights from HIV and COVID-19 campaigns […]
Overview of Gavi’s support for HPV vaccination programs in low and middle income countries (LMICs) – Q&A Session
The session explored gender equity in HPV vaccination, clarifying that current focus is on girls due to cervical cancer burden, with boys possibly included in future strategies. Participants discussed Bangladesh’s upcoming national rollout in 2023, building on prior pilot success. Questions addressed the long-term immunity of single- or two-dose regimens, with evidence showing durable protection […]
HPV related disease burden, mortality, social and economic impact – Q&A
The session concluded with an open discussion highlighting key cross‑cutting themes from country presentations: the profound social stigma and poverty linked to cervical cancer, and increasing governmental commitment across South Asia to address the disease. Questions focused on the role of behavioral versus biological risk factors, gaps in cancer registries, and the paradox of low […]
Cervical cancer screening programs implementation – Q&A Session
The session highlighted the uneven progress of cervical cancer screening across South Asia, emphasizing both achievements and persistent challenges. Bhutan’s transition to HPV-based screening, combined with high vaccination coverage, was presented as a regional benchmark for integrated prevention. In contrast, India, Bangladesh, and Nepal continue to rely primarily on VIA-based programs, which face obstacles in […]
Cervical Cancer Screening Landscape – Q&A Session
The Q&A session focused on Turkey’s centralized HPV screening program and its cost-effectiveness. Dr. Gultekin explained that initial large tenders and early adoption allowed screening costs to drop below USD 5 per woman, with new validated national kits expected to reduce this further to under USD 1. Questions addressed management of equivocal results (retesting is […]